Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?

Alzheimer's Research and Therapy

Volumn 6, Issue 5-8, 2014, Pages

  Rafii, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; DISEASE COURSE; DOWN SYNDROME; GENE; GENE MUTATION; HUMAN; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

EID: 84907055448     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-014-0060-7     Document Type: Review

References (28)

1. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. CR Jack Jr, DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, RC Petersen, JQ Trojanowski, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09)70299-6 20083042
2. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. RJ Bateman, C Xiong, TL Benzinger, AM Fagan, A Goate, NC Fox, DS Marcus, NJ Cairns, X Xie, TM Blazey, DM Holtzman, A Santacruz, V Buckles, A Oliver, K Moulder, PS Aisen, B Ghetti, WE Klunk, E McDade, RN Martins, CL Masters, R Mayeux, JM Ringman, MN Rossor, PR Schofield, RA Sperling, S Salloway, JC Morris, N Engl J Med 2012 367 795 804 10.1056/NEJMoa1202753 22784036
3. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. EM Reiman, YT Quiroz, AS Fleisher, K Chen, C Velez-Pardo, M Jimenez-Del-Rio, AM Fagan, AR Shah, S Alvarez, A Arbelaez, M Giraldo, N Acosta-Baena, RA Sperling, B Dickerson, CE Stern, V Tirado, C Munoz, RA Reiman, MJ Huentelman, GE Alexander, JB Langbaum, KS Kosik, PN Tariot, F Lopera, Lancet Neurol 2012 11 1048 1056 10.1016/S1474-4422(12)70228-4 23137948
4. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. D Scheuner, C Eckman, M Jensen, X Song, M Citron, N Suzuki, TD Bird, J Hardy, M Hutton, W Kukull, E Larson, E Levy-Lahad, M Viitanen, E Peskind, P Poorkaj, G Schellenberg, R Tanzi, W Wasco, L Lannfelt, D Selkoe, S Younkin, Nat Med 1996 2 864 870 10.1038/nm0896-864 8705854
5. Updated national birth prevalence estimates for selected birth defects in the United States, 2004-2006. SE Parker, CT Mai, MA Canfield, R Rickard, Y Wang, RE Meyer, P Anderson, CA Mason, JS Collins, RS Kirby, A Correa, Birth Defects Res A 2010 88 1008 1016 10.1002/bdra.20735
6. Genetic and host factors for dementia in Down's syndrome. N Schupf, GH Sergievsky, Br J Psychiatry 2002 180 405 410 10.1192/bjp.180.5.405 11983636
7. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. GG Glenner, CW Wong, Biochem Biophys Res Commun 1984 122 1131 1135 10.1016/0006-291X(84)91209-9 6236805
8. Alzheimer-like cholinergic deficiency in Down syndrome. CM Yates, J Simpson, AF Maloney, A Gordon, AH Reid, Lancet 1980 2 979 10.1016/S0140-6736(80)92137-6 6107618
9. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. CA Lemere, JK Blusztajn, H Yamaguchi, T Wisniewski, TC Saido, DJ Selkoe, Neurobiol Dis 1996 3 16 32 10.1006/nbdi.1996.0003 9173910
10. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. N Schupf, B Patel, W Silverman, WB Zigman, N Zhong, B Tycko, PD Mehta, R Mayeux, Neurosci Lett 2001 301 199 203 10.1016/S0304-3940(01)01657-3 11257432
11. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. BL Handen, AD Cohen, U Channamalappa, P Bulova, SA Cannon, WI Cohen, CA Mathis, JC Price, WE Klunk, Alzheimers Dement 2012 8 496 501 10.1016/j.jalz.2011.09.229 23102120
12. Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. BT Hyman, HL West, GW Rebeck, F Lai, DM Mann, Arch Neurol 1995 52 373 378 10.1001/archneur.1995.00540280059019 7710373
13. Onset of dementia is associated with apolipoprotein E epsilon4 in Down's syndrome. N Schupf, D Kapell, JH Lee, W Zigman, B Canto, B Tycko, R Mayeux, Ann Neurol 1996 40 799 801 10.1002/ana.410400518 8957023
14. Molecular mapping of Alzheimer-type dementia in Down's syndrome. VP Prasher, MJ Farrer, AM Kessling, EM Fisher, RJ West, PC Barber, AC Butler, Ann Neurol 1998 43 380 383 10.1002/ana.410430316 9506555
15. Age related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome: quantitative regional analysis and comparison with Alzheimer's disease. PR Hof, C Bouras, DP Perl, DL Sparks, N Mehta, JH Morrison, Arch Neurol 1995 52 379 391 10.1001/archneur.1995.00540280065020 7710374
16. Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. JS Krasuski, GE Alexander, B Horwitz, SI Rapoport, MB Schapiro, Am J Psychiatry 2002 159 74 81 10.1176/appi.ajp.159.1.74 11772693
17. Longitudinal Study of Neuropsychological Function in Older Adults with Down Syndrome. JV Haxby, MB Schapiro, Down Syndrome and Alzheimer's Disease Wiley-Liss, New York, Nadel L, Epstein CJ, 1992 35 50
18. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. M Shin, LM Besser, JE Kucik, C Lu, C Siffel, A Correa, Pediatrics 2009 124 1565 1571 10.1542/peds.2009-0745 19948627
19. Atypical aging in Down syndrome. WB Zigman, Dev Disabil Res Rev 2013 18 51 67 10.1002/ddrr.1128 23949829
20. Mortality associated with Down's syndrome in the US from 1983 to 1997: a population-based study. Q Yang, SA Rasmussen, JM Friedman, Lancet 2002 359 1019 1025 10.1016/S0140-6736(02)08092-3 11937181
21. Aging and dementia among adults with mental retardation and Down syndrome. W Silverman, WB Zigman, H Kim, S Krinsky-McHale, HM Wisniewski, Topic Geriatr Rehabil 1998 13 49 64 10.1097/00013614-199803000-00007
22. Behavioural disturbance in people with Down's syndrome and dementia. VP Prasher, A Filer, J Intellect Disabil Res 1995 39 432 436 10.1111/j.1365-2788.1995.tb00547.x 8555719
23. Incidence and prevalence of dementia in elderly adults with mental retardation without Down syndrome. WB Zigman, N Schupf, DA Devenny, C Miezejeski, R Ryan, TK Urv, R Schubert, W Silverman, Am J Ment Retard 2004 109 126 141 10.1352/0895-8017(2004)109<126:IAPODI>2.0.CO;2 15000676
24. Guidance for Industry: Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease Department of Health and Human Services, Food and Drug Administration, Washington, DC 2013
25. Regulatory innovation and drug development for early-stage Alzheimer's disease. N Kozauer, R Katz, N Engl J Med 2013 368 1169 1171 10.1056/NEJMp1302513 23484795
26. A four year prospective study of age-related cognitive change in adults with Down's syndrome. C Oliver, L Crayton, A Holland, S Hall, J Bradbury, Psychol Med 1998 28 1365 1377 10.1017/S0033291798007417 9854278
27. Neuropsychological assessment of older adults with Down's syndrome: an epidemiological study using the Cambridge Cognitive Examination (CAMCOG). J Hon, FA Huppert, AJ Holland, P Watson, Br J Clin Psychol 1999 38 155 165 10.1348/014466599162719 10389597
28. Sequence of cognitive decline in dementia in adults with Down's syndrome. DA Devenny, SJ Krinsky-McHale, G Sersen, WP Silverman, J Intellect Disabil Res 2000 44 654 665 10.1046/j.1365-2788.2000.00305.x 11115020